NCHR Comment on Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products
NCHR backs FDA's proposed guidance to collect standardized race/ethnicity data in clinical trials, which is crucial for addressing safety and efficacy disparities. We also urge a new category, mandatory implementation, and improved diversity to ensure accurate representation and meaningful efficacy and safety data
Читать дальше...